In studies of the serous subtype of epithelial ovarian cancer, miR-506 was found to be a robust EMT inhibitor through direct targeting of the E-cad repressor SNAI2 [67], the vimentin gene (VIM) and N-cad gene (CDH2) [68], suggesting that miR-506 inhibits multiple targets in the EMT network and is associated with good prognosis in epithelial ovarian cancer. This evidence concerns the gene VIM and ovarian carcinoma.